Does smoking cessation with varenicline worsen vascular endothelial function?

被引:15
|
作者
Umeda, Akira [1 ]
Kato, Toru [2 ]
Yamane, Tateki [1 ]
Yano, Heiichi [1 ]
Ieiri, Tamio [1 ]
Miyagawa, Kazuya [3 ]
Takeda, Hiroshi [3 ]
Okada, Yasumasa [4 ]
机构
[1] Int Univ Hlth & Welf, Dept Internal Med, Shioya Hosp, Otawara, Tochigi, Japan
[2] Natl Hosp Org Tochigi Med Ctr, Dept Clin Res, Shimotsuke, Tochigi, Japan
[3] Int Univ Hlth & Welf, Sch Pharm, Dept Pharmacol, Otawara, Tochigi, Japan
[4] Natl Hosp Org Murayama Med Ctr, Dept Internal Med, Tokyo, Japan
来源
BMJ OPEN | 2013年 / 3卷 / 06期
关键词
FLOW-MEDIATED VASODILATION; HEALTHY-YOUNG ADULTS; CARDIOVASCULAR-DISEASE; PASSIVE SMOKING; RISK; METAANALYSIS; DYSFUNCTION; EVENTS; ATHEROSCLEROSIS; DILATATION;
D O I
10.1136/bmjopen-2013-003052
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: A meta-analysis suggested that the use of varenicline, which is a partial agonist of nicotinic acetylcholine receptors and is effective in smoking cessation, increases the risk of cardiovascular events within 52 weeks of starting treatment. Defining these events as occurring during drug treatment (usually for 12 weeks) or within 30 days of discontinuation, another meta-analysis showed that the risk was statistically insignificant. In the present study, we aimed to clarify the effect of varenicline-assisted smoking cessation on vascular endothelial function assessed by flow-mediated vasodilation (FMD). Design: Before-after and time-series. Setting: Tochigi Prefecture, Japan. Participants: Data of 85 participants who visited nicotine-dependent outpatient services were reviewed. FMD was repeatedly measured in 33 of the 85 participants. Inclusion criteria: 20 years and older, Brinkman index >= 200, Tobacco Dependence Screener >= 5 and stated motivation to quit smoking. Interventions: Each participant was treated with varenicline titrated up to 1.0 mg twice daily (for 12 weeks in total). Primary and secondary outcome measures: Participants were evaluated by FMD prior to, and 3 months after, complete smoking cessation. Follow-up FMD measurements were carried out every 3 months if possible. Changes in FMD during varenicline use were also evaluated. Results: FMD was significantly increased from 4.0 +/- 1.8% to 5.5 +/- 2.2% (p<0.01, n=22) 3 months after complete cessation. Although the timecourse of FMD in most of the cases showed an increase with fluctuations, there was an exceptional case where FMD decreased over the 9 months following complete cessation. Although statistically insignificant, FMD also increased during varenicline use (from 3.7 +/- 2.7% to 4.3 +/- 2.8%, n=11). Conclusions: Our observations suggest that in ceasing smokers, varenicline and smoking cessation do not lead to a worsening of the vascular endothelial function.
引用
收藏
页数:6
相关论文
共 50 条
  • [41] Pharmacoeconomic Spotlight on Varenicline as an Aid to Smoking Cessation
    Keating, Gillian M.
    Lyseng-Williamson, Katherine A.
    [J]. CNS DRUGS, 2010, 24 (09) : 797 - 800
  • [42] Varenicline: New treatment with efficacy in smoking cessation
    Reus, Victor I.
    Obach, R. Scott
    Coe, Jotham W.
    Faessel, Helene
    Rollema, Hans
    Watsky, Eric
    Reeves, Karen
    [J]. DRUGS OF TODAY, 2007, 43 (02) : 65 - 75
  • [43] Behavioral Counseling and Varenicline Treatment for Smoking Cessation
    Swan, Gary E.
    McClure, Jennifer B.
    Jack, Lisa M.
    Zbikowski, Susan M.
    Javitz, Harold S.
    Catz, Sheryl L.
    Deprey, Mona
    Richards, Julie
    McAfee, Timothy A.
    [J]. AMERICAN JOURNAL OF PREVENTIVE MEDICINE, 2010, 38 (05) : 482 - 490
  • [44] Varenicline for smoking cessation - Definite promise, but no panacea
    Klesges, Robert C.
    Johnson, Karen C.
    Somes, Grant
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (01): : 94 - 95
  • [45] Varenicline vs Bupropion and Placebo for Smoking Cessation
    Bowman, Thomas S.
    [J]. CURRENT CARDIOVASCULAR RISK REPORTS, 2007, 1 (05) : 357 - 357
  • [46] Varenicline Aids Smoking Cessation in Black Smokers
    Slomski, Anita
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 328 (07): : 610 - 610
  • [47] Efficacy of Varenicline for Smoking Cessation in Bipolar Disorder
    Goldberg, Joseph F.
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2014, 75 (07) : 773 - 774
  • [48] Varenicline Attenuates Gender Disparities in Smoking Cessation
    Smith, Philip H.
    Weinberger, Andrea
    Kaufman, Mira
    Cosgrove, Kelly
    Picciotto, Marina
    Mineur, Yann
    Mazure, Carolyn
    McKee, Sherry A.
    [J]. JOURNAL OF WOMENS HEALTH, 2014, 23 (10) : 870 - 870
  • [49] Varenicline - Increased cardiovascular risk in smoking cessation?
    Dewenter, M.
    El-Armouche, A.
    [J]. KARDIOLOGE, 2012, 6 (03): : 240 - 243
  • [50] Varenicline for Smoking Reduction Prior to Cessation In Reply
    Ebbert, Jon O.
    Hughes, John R.
    West, Robert J.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 313 (22): : 2285 - 2286